> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# 3 FDA Clinical Trial Guidances Analyzed
- URL: https://www.fdaweb.com/3-fda-clinical-trial-guidances-analyzed/
- Published: 2024-09-26T12:00:00.000Z
- Updated: 2026-09-14T14:42:31.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5157861

Four Ropes & Gray attorneys say one final and two draft guidances recently published by FDA “reflect continued efforts … to modernize clinical trial policies, including by promoting flexibility in clinical trial design and capitalizing on the technological advances and efficiencies of the modern healthcare landscape.” In an online [post](https://www.ropesgray.com/en/insights/alerts/2024/09/three-of-a-kind-fda-guidance-documents-provide-recommendations-on-non-traditional?ref=fdaweb.com), the attorneys note the agency’s acknowledgment that the non-traditional clinical trial designs can present novel challenges relating to clinical trial compliance, quality, accuracy, and generalizability.

“Given these potential issues,” they say, “FDA has cautioned that non-traditional trial designs may not be appropriate for all clinical development programs and has noted that they may create additional burdens that will need to be carefully balanced.”

Discussing the final guidance on decentralized clinical trials, the attorneys say the most notable changes from the draft cover:

- no task log for “local healthcare provider (HCP)” activities;
- ensuring qualifications of local HCPs;
- clarifying expectations for investigator oversight of local HCPs;
- additional examples of data variability risks and mitigation efforts; and
- clarification on the identification of a physical location for regulatory inspections.

The post says the key aspects of a draft guidance on routine clinical practice trials are:

- appropriate drugs for trials in routine clinical practice;
- sponsor engagements with healthcare institutions;
- activities appropriate for trial personnel versus local HCPs;
- investigator supervision of local HAPs; and
- use of a quality-by-design approach.

The key provisions in the draft guidance on oncology multiregional clinical trial (MRCT) development programs are:

- U.S. population representativeness;
- standard of care considerations;
- considerations for analysis of data from MRCTs; and
- early consultation with FDA and other regulatory authorities.